Last Updated:
10 Mar 2026, 03:29:57 PM (IST)
Jagsonpal Pharmaceuticals Limited
NSE: JAGSNPHARM BSE: JAGSNPHARM
NSE
176.71
8.44 (5.02%)
Prev Close
168.27
Open Price
180
Volume
1,997,600
Today Low / High
175.2 / 192.5
52 WK Low / High
155 / 301.65
Range
168 - 186
BSE
176.90
7.20 (4.24%)
Prev Close
169.7
Open Price
178.05
Volume
73,348
Today Low / High
172.3 / 191.9
52 WK Low / High
154.9 / 301.8
Range
168 - 186
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 176.71 (target range: 168 - 186), reflecting a change of 8.44 (5.01575%). On the BSE, it is listed at 176.9 (target range: 168 - 186), showing a change of 7.2 (4.24278%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Jagsonpal Pharmaceuticals Limited Graph
Jagsonpal Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Jagsonpal Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 176.71, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 176.90 | 178.67 | 160.80 - 196.54 |
| 180.44 | 144.35 - 216.53 | ||
| 182.21 | 127.54 - 236.87 | ||
| Bearish Scenario | 176.90 | 175.13 | 157.62 - 192.64 |
| 173.36 | 138.69 - 208.03 | ||
| 171.59 | 120.12 - 223.07 |
Overview of Jagsonpal Pharmaceuticals Limited
ISIN
INE048B01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
55,507
Market Cap
11,632,249,255
Last Dividend
2.5
Official Website
IPO Date
2002-07-01
DCF Diff
-267.42
DCF
502
Financial Ratios Every Investor Needs
Stock Dividend of JAGSNPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-12 | September 12, 25 | 2.5 | 2.5 | 2025-09-12 | 2025-10-24 | |
| 2024-09-06 | September 06, 24 | 2 | 5 | 2024-09-06 | 2024-10-18 | |
| 2023-08-21 | August 21, 23 | 2 | 5 | 2023-08-21 | 2023-09-30 | |
| 2021-10-29 | October 29, 21 | 1.6 | 4 | 2021-11-01 | 2021-11-18 | |
| 2021-09-22 | September 22, 21 | 0.4 | 1 | 2021-09-23 | 2021-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 268.72 Cr | 96.44 Cr | 172.28 Cr | 0.6411 | 0.00 Cr | 71.36 Cr | 43.55 Cr | 55.36 Cr | 8.26 | 51.07 Cr | 0.2060 |
| 2024-03-31 | 208.70 Cr | 143.44 Cr | 65.26 Cr | 0.3127 | 0.00 Cr | 3.81 Cr | 21.40 Cr | 22.46 Cr | 3.40 | 32.35 Cr | 0.1076 |
| 2023-03-31 | 236.71 Cr | 93.10 Cr | 143.61 Cr | 0.6067 | 0.00 Cr | 5.76 Cr | 34.33 Cr | 26.72 Cr | 4.08 | 36.40 Cr | 0.1129 |
| 2022-03-31 | 217.58 Cr | 96.11 Cr | 128.30 Cr | 0.5897 | 0.00 Cr | 10.17 Cr | 24.55 Cr | 18.86 Cr | 2.88 | 28.45 Cr | 0.0867 |
| 2021-03-31 | 187.88 Cr | 80.93 Cr | 106.94 Cr | 0.5692 | 0.35 Cr | 4.07 Cr | 18.79 Cr | 17.06 Cr | 2.60 | 23.47 Cr | 0.0908 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 128.73 Cr | 278.26 Cr | 38.31 Cr | 239.9500 Cr | 9.24 Cr | -119.49 Cr | 15.20 Cr | 8.84 Cr | 0.00 Cr | 0.67 Cr | 17.39 Cr | 25.9040 Cr |
| 2024-03-31 | 12.76 Cr | 217.08 Cr | 29.68 Cr | 187.4020 Cr | 8.94 Cr | -3.82 Cr | 15.00 Cr | 9.30 Cr | 1.29 Cr | 0.00 Cr | 4.70 Cr | 19.1280 Cr |
| 2023-03-31 | 11.05 Cr | 194.95 Cr | 36.06 Cr | 158.8903 Cr | 6.00 Cr | -5.05 Cr | 20.68 Cr | 24.28 Cr | 0.61 Cr | 0.00 Cr | 3.38 Cr | 27.5716 Cr |
| 2022-03-31 | 25.14 Cr | 168.45 Cr | 37.60 Cr | 130.8556 Cr | 5.25 Cr | -25.14 Cr | 29.74 Cr | 22.37 Cr | 0.00 Cr | 0.00 Cr | 29.06 Cr | 26.9720 Cr |
| 2021-03-31 | 61.88 Cr | 164.20 Cr | 42.27 Cr | 121.9291 Cr | 6.79 Cr | -55.09 Cr | 29.72 Cr | 23.35 Cr | 13.75 Cr | 0.00 Cr | 12.06 Cr | 40.3967 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 55.3000 Cr | -45.1470 Cr | -11.6980 Cr | 54.9520 Cr | -1.5450 Cr | 11.2150 Cr | -0.3480 Cr | 55.3610 Cr | -0.9020 Cr | -13.2290 Cr | 0.0010 Cr |
| 2024-03-31 | 35.1660 Cr | -24.5480 Cr | -8.9110 Cr | 34.9180 Cr | 1.7070 Cr | 12.7600 Cr | -0.2480 Cr | 22.4630 Cr | -0.6330 Cr | -13.0990 Cr | 5.3100 Cr |
| 2023-03-31 | 46.6541 Cr | -57.6707 Cr | -0.4567 Cr | 46.3365 Cr | -11.4733 Cr | 11.0531 Cr | -0.3176 Cr | 34.8085 Cr | -0.0440 Cr | 0.0000 Cr | 9.0657 Cr |
| 2022-03-31 | 6.9140 Cr | -25.7790 Cr | -17.5520 Cr | 5.1306 Cr | -36.4169 Cr | 26.0293 Cr | -0.4675 Cr | 27.3191 Cr | -6.7880 Cr | -10.4790 Cr | -0.0176 Cr |
| 2021-03-31 | 28.2224 Cr | -2.2643 Cr | -6.8282 Cr | 27.7533 Cr | 19.1299 Cr | 58.9429 Cr | -0.4691 Cr | 21.8723 Cr | 0.0000 Cr | -2.6200 Cr | -0.3995 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 72.95 Cr | 26.45 Cr | 46.49 Cr | 0.6374 | 13.88 Cr | 10.95 Cr | 1.67 | 17.16 Cr | 0.1501 |
| 2025-09-30 | 74.47 Cr | 27.23 Cr | 47.24 Cr | 0.6344 | 14.05 Cr | 12.57 Cr | 1.88 | 19.46 Cr | 0.1689 |
| 2025-06-30 | 75.61 Cr | 26.93 Cr | 48.69 Cr | 0.6439 | 11.86 Cr | 10.80 Cr | 1.60 | 17.04 Cr | 0.1428 |
| 2025-03-31 | 58.56 Cr | 21.72 Cr | 36.84 Cr | 0.6291 | 6.41 Cr | 6.58 Cr | 0.98 | 8.44 Cr | 0.1124 |
| 2024-12-31 | 74.03 Cr | 26.52 Cr | 47.51 Cr | 0.6418 | 13.42 Cr | 31.99 Cr | 4.74 | 41.34 Cr | 0.4322 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 12.79 Cr | 146.52 Cr | 159.31 Cr | 22.57 Cr | 15.85 Cr | 201.79 Cr | 8.19 Cr | 299.03 Cr | 46.19 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 128.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -239.95 Cr |
| 2025-03-31 | 128.73 Cr | 0.00 Cr | 128.73 Cr | 13.18 Cr | 15.20 Cr | 161.19 Cr | 8.84 Cr | 278.26 Cr | 38.31 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 77.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -197.10 Cr |
| 2024-09-30 | 18.44 Cr | 59.51 Cr | 77.85 Cr | 19.49 Cr | 16.80 Cr | 138.79 Cr | 10.00 Cr | 258.20 Cr | 61.10 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 10.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 6.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 31.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 11.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 5.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2004-07-20 | July 20, 04 | 8:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chief Operating Officer
Amrut Medhekar
Gender: male
Year Born:
General Manager of Human Resource Admin
Bharat Chugh
Gender: male
Year Born:
MD & Director
Manish Gupta
Gender: male
Year Born: 1967
Chief Financial Officer
Nirav Niranjanakumar Vora
Gender: male
Year Born:
Company Secretary & Compliance Officer
Pratham Rawal
Gender: male
Year Born:
Vice President of Sales & Marketing
Sudeep Paul
Gender: Not Specified
Year Born:
FAQs about Jagsonpal Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Manish Gupta.
What is the current market price of the stock?
The current price is ₹173.90.
What is the 52-week price range?
The range is ₹155-301.65.
What is the market capitalization of the company?
The market capitalization is ₹1,163.22 crores.
What is the dividend yield?
The dividend yield is 1.44%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.88.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Jagsonpal Pharmaceuticals Limited (ISIN: INE048B01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,163.22 crores and an average daily volume of 55,507 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.5.